01.05.2023 Krankenkassenantrag Mirvetuximab soravtansine genehmigt - MII IG Kerndatensatz-Modul Molekulares Tumorboard v2027.0.0-ballot.1

MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Beispiel ClaimResponse: 01.05.2023 Krankenkassenantrag Mirvetuximab soravtansine genehmigt

German

Profile: MII PR MTB Anwort Kostenuebernahme version: 2027.0.0-ballot.1

status: Active

type: institutional

use: Claim

patient: Kim Musterperson (no stated gender), DoB: 1956-03-14

created: 2023-05-01

insurer: Organization Example General Hospital

request: Claim: status = active; type = institutional; use = claim; created = 2023-03-10; priority = Normal

outcome: Processing Complete

IG © 2024+ Medizininformatik-Initiative. Package de.medizininformatikinitiative.kerndatensatz.mtb#2027.0.0-ballot.1 basiert auf FHIR 4.0.1. Erstellt 2026-09-15
Links: Inhaltsverzeichnis | QA-Bericht | netzwerk-universitaetsmedizin.de | medizininformatik-initiative.de | Impressum
HL7®, FHIR® and the FHIR flame design are registered trademarks of Health Level Seven International. Their use does not constitute endorsement by HL7.